PREVALENCE OF HEPATITIS B VIRUS AMONG HIV PATIENTS BETWEEN 15 - 35 YEARS ATTENDING RUKUNYU HOSPITAL, KAMWENGE DISTRICT.A CROSS-SECTIONAL STUDY.
DOI:
https://doi.org/10.51168/fgyt3p58Keywords:
Prevalence, Hepatitis B Virus, HIV Patients, Rukunyu Hospital, Kamwenge DistrictAbstract
Background
Hepatitis B virus (HBV) is a viral infection comprised by the presence of hepatic leucocytes HBVs in the cytoplasm of the hepatocytes. Hepatitis B viral infection attacks the liver and causes acute and chronic disease.
Method
A cross-sectional study was carried out at Rukunyu Hospital Kamwenge to determine the prevalence of hepatitis B virus infection among HIV patients aged 15 - 35 years old on 111 respondents. Quantitative data collection was used, and the questionnaires were given to the consented participants to fill out for current data collection for new cases. A laboratory medical book register was requested from laboratory staff for old cases to find the prevalence of HBV.
Results
A total of 111 HIV patients were tested for HBV of which 23 HIV patients tested positive and 88 tested negative.Socio demographically, most of participants were females 63(56.8%) and males being 48(43.2%) Married participants being 61(55.0%) , single 27(24.3%) , divorced were 14(12.6%) participants and last being widow/widower 9(8.1%). The majority of the participants had started and reached at least in secondary level, however, some few were ongoing students and the prevalence of Hepatitis B virus among HIV patients was high in the age group of 26-30 years old.
Conclusion
The prevalence of Hepatitis B was highest among the ages of 26-30 years old, the prevalence and treatment challenges are still the biggest problem due to risk factors of HBV infection such as having multiple sex partners, sharing of clothes, blood transfusion, and intravenous injections seen to bring added risks.
Recommendation
As per the research study findings, there is a need for further research to be done such as setting up more health centers or hospitals to provide HBV screening among patients living with HIV to curb the HBV spread.
References
Nzaramba, Daniel, Benson Musinguzi, Ivans Gyagenda, John Lusoma Ntemi, Josephat Kighoma, PatrickSobere, and FrankSsedyabane. "Prevalence of LiverFibrosis in Hepatitis B Virus Infection Using Aspartate Aminotransferase to Platelet Ratio Index (APRI) Score at RukunyuHospital, Kamwenge District, South Western Uganda." (2022). https://doi.org/10.21203/rs.3.rs-1725083/v1 PMid:36163018 PMCid: PMC9512986
Hepatitis B. (april,2024.). Retrieved October 29, 2024, from https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
Rajamoorthy, Y., Taib, N. M., Mudatsir, M., Harapan, H., Wagner, A. L., Munusamy, S., ... & Radam, A. (2020). Risk behaviors related to hepatitis B virus infection among adults in Malaysia: A cross-sectional household survey. Clinical Epidemiology and Global Health, 8(1), 76-82. https://doi.org/10.1016/j.cegh.2019.04.011
Said, Z. N. A., & El-Sayed, M. H. (2022). The challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings. World Journal of Hepatology, 14(7), 1333. https://doi.org/10.4254/wjh.v14.i7.1333 PMid:36158908 PMCid: PMC9376770
Chiesa, A., Ochola, E., Oreni, L., Vassalini, P., Rizzardini, G., & Galli, M. (2020). Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon? PloS one, 15(11), e0242278. https://doi.org/10.1371/journal.pone.0242278 PMid:33206693 PMCid: PMC7673526
World Health Organization. Hepatitis B. [ APRIL; 2024 ];https://www.who.int/news-room/fact-sheets/detail/hepatitis-b,2019
World Health Organization. Hepatitis B. [ Jun; 2022 ];https://www.who.int/news-room/fact-sheets/detail/hepatitis-b 2015
Kish, L. (1976). Optima and Proxima in linear sample designs. Journal of the Royal Statistical Society Series A: Statistics in Society, 139(1), 80-95. https://doi.org/10.2307/2344384
Downloads
Published
Issue
Section
License
Copyright (c) 2024 IVAN BYAMUKAMA , AWACH OGWAL IVAN (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The journal publishes under the Attribution-Noncommercial-NoDerivatives 4.0 international (CCBY-NC-ND 4.0) license which allows you to Share, Copy and redistribute the materials in any medium or format. The licensor cannot revoke these freedoms as long as you follow the license terms;
- Attribution: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- Non-commercial: You may not use the material for commercial purposes. Commercial use is one primarily intended for commercial advantage or monetary compensation.
- No Derivatives: if you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions: You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
